Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn’s disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is different i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Li, Xiaofei, Shi, Yanting, Zhou, He, Yang, Gang, Li, Ruixia, Wu, Tong, Liang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613675/
https://www.ncbi.nlm.nih.gov/pubmed/37908975
http://dx.doi.org/10.3389/fphar.2023.1259183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613675/
https://www.ncbi.nlm.nih.gov/pubmed/37908975
http://dx.doi.org/10.3389/fphar.2023.1259183

Ejemplares similares